Twist Bioscience Corp (TWST): Revenue
$459.43M
Year ended 2026-09-30
+23.3%
3-year compound annual growth
+28.3%
5-year compound annual growth
| Period ended | Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2026-09-30 | $459.43M | +22.0% | 2026-11-16, From 2025-10-01 |
| 2025-09-30 | $376.57M | +20.3% | 2026-11-16, From 2024-10-01 |
| 2024-09-30 | $312.97M | +27.7% | 2026-11-16, From 2023-10-01 |
| 2023-09-30 | $245.11M | +20.4% | 2025-11-17, From 2022-10-01 |
| 2022-09-30 | $203.56M | +53.8% | 2024-11-18, From 2021-10-01 |
| 2021-09-30 | $132.33M | +46.9% | 2023-11-21, From 2020-10-01 |
| 2020-09-30 | $90.10M | +65.7% | 2023-06-05, From 2019-10-01 |
| 2019-09-30 | $54.38M | +113.9% | 2021-11-23, From 2018-10-01 |
| 2018-09-30 | $25.43M | +136.2% | 2020-11-27, From 2017-10-01 |
| 2017-09-30 | $10.77M | n/a | 2019-12-13, From 2016-10-01 |
Revenue at similar companies
| Company | Year ended | Revenue | Change YoY |
|---|---|---|---|
| Twist Bioscience Corp (TWST) | 2026-09-30 | $459.43M | +22.0% |
| Tarsus Pharmaceuticals, Inc. (TARS) | 2025-12-31 | $451.36M | +146.7% |
| ADMA Biologics, Inc. (ADMA) | 2025-12-31 | $510.17M | +19.6% |
| Immunocore Holdings plc (IMCR) | 2025-12-31 | $400.02M | +29.0% |
| Krystal Biotech, Inc. (KRYS) | 2025-12-31 | $389.13M | +33.9% |
| Repligen Corp (RGEN) | 2025-12-31 | $738.26M | +16.4% |
| Adaptive Biotechnologies Corp (ADPT) | 2025-12-31 | $276.98M | +54.8% |
| Vericel Corp (VCEL) | 2025-12-31 | $276.26M | +16.5% |
| Iovance Biotherapeutics, Inc. (IOVA) | 2025-12-31 | $263.50M | +60.6% |
Compare TWST, TARS, ADMA, IMCR side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗